Indupro Inc. has announced a $85 million series A financing to support its work on precisely defining the spatial proximity of proteins on the surface of cells with high therapeutic potential across a broad range of indications and applications, including for the treatment of cancer and autoimmune diseases.
Myeloproliferative neoplasms (MPNs) can only be cured, to date, using allogeneic stem cell transplantation which, in turn, only works for up to 20% of patients. As calreticulin (CALR) frameshift mutations are the second most common cause of MPNs, targeting this endoplasmic reticulum resident protein is one of the strategies emerging at the forefront of hematological malignancies research.
Sanofi SA and Seagen Inc. have reported antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to topoisomerase I inhibitors through a linker reported to be useful for the treatment of cancer.
McGill University, Université de Montreal, Yeda Research and Development Co. Ltd. and Yissum Research Development Co. have jointly developed anisomycin analogues reported to be useful for the treatment of giardiasis, leishmaniasis, toxoplasmosis and trypanosomiasis.
Actelion Pharmaceuticals Ltd. has identified pyrazolopyrrolopyridazines acting as platelet-derived growth factor receptor β (PDGFR-β, PDGFRB) inhibitors reported to be useful for the treatment of pulmonary arterial hypertension.
Curadev Pharma Ltd. has patented proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting agent via linker acting as HPK1 inhibitors and thus reported to be useful for the treatment of cancer, viral infections and immunological disorders.
A Caregen Co. Ltd. patent details new peptides acting as autophagy and phagocytosis inducers potentially useful for the treatment of hyperpigmentation.
Cholangiocarcinoma accounts for about 3% of all gastric tumors. Mutant KRAS is the most prevalent oncogene in cholangiocarcinoma, suggesting a potential role for KRAS inhibitors as a therapeutic approach.
Bivictrix Therapeutics plc’s BVX-001, a first-in-class Bi-Cygni bispecific antibody-drug conjugate (ADC) for the treatment of acute myeloid leukemia (AML), has demonstrated a favorable toxicity profile in an industry standard toxicology model.
RSS
